薬剤比較
Saxagliptin vs Pioglitazone
SaxagliptinとPioglitazoneの比較：2型糖尿病に対するDPP-4阻害薬とTZD。心不全リスク、体重増加、浮腫、インスリン抵抗性、副作用を比較します。
このページには比較できる項目がありません。
臨床的背景
This comparison is triggered when type 2 diabetes patients on metformin require add-on oral therapy and must balance DPP-4 incretin effects against TZD insulin-sensitizing benefits amid cardiovascular and fluid-retention concerns.
結論
Saxagliptin generally suits patients prioritizing weight neutrality and lower edema risk, while Pioglitazone may be considered for significant insulin resistance, with neither inherently superior and selection based on individual risk profiles.
すべての薬剤比較